Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers

16:29 EDT 23 May 2018 | SCRIP

In Phase III KEYNOTE-407 of squamous NSCLC, Keytruda/chemo combo shows overall survival benefit, which was reassuring news for doctors –...

Original Article: Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers

More From BioPortfolio on "Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers"